» Articles » PMID: 18034879

International Web-based Consultation on Priorities for Translational Breast Cancer Research

Overview
Specialty Oncology
Date 2007 Nov 24
PMID 18034879
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Large numbers of translational breast cancer research topics have been completed or are underway, but they differ widely in their immediate and/or future importance to clinical management. We therefore conducted an international Web-based consultation of breast cancer professionals to identify the topics most widely considered to be of highest priority.

Methods: Potential participants were contacted via two large e-mail databases and asked to register, at a Web site, the issues that they felt to be of highest priority. Four hundred nine questions were reduced by a steering committee to 70 unique issues, and registrants were asked to select the 6 questions they considered to be the most important.

Results: Votes were recorded from 420 voters (2,520 votes) from 48 countries, with 48% of voters coming from North America. Half of the voters identified themselves as clinicians, with the remainder being academics, research scientists, or pathologists. The highest priority was to identify molecular signatures to select patients who could be spared chemotherapy, which gained about 50% more votes than the second topic and was consistently voted top by voters in North America, Europe, and the rest of the world. Research scientists voted the determination of the role of stem cells in breast cancer development, progression, and treatment sensitivity as the most important issue, but this was considered the sixth priority for clinicians and fourth overall.

Conclusion: This exercise may bring a greater focus of research resources onto issues voted as top priorities.

Citing Articles

Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.

Rohan T, Wang Y, Couch F, Feigelson H, Greenlee R, Honda S Breast Cancer Res Treat. 2025; .

PMID: 39832051 DOI: 10.1007/s10549-024-07599-x.


Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.

Yaghjyan L, Heng Y, Baker G, Murthy D, Mahoney M, Rosner B Br J Cancer. 2024; 131(2):325-333.

PMID: 38849477 PMC: 11263693. DOI: 10.1038/s41416-024-02743-2.


Reliability of CD44, CD24, and ALDH1A1 immunohistochemical staining: Pathologist assessment compared to quantitative image analysis.

Yaghjyan L, Heng Y, Baker G, Bret-Mounet V, Murthy D, Mahoney M Front Med (Lausanne). 2023; 9:1040061.

PMID: 36590957 PMC: 9794585. DOI: 10.3389/fmed.2022.1040061.


Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study.

Rohan T, Ginsberg M, Wang Y, Couch F, Feigelson H, Greenlee R BMJ Open. 2021; 11(10):e053397.

PMID: 34702732 PMC: 8549665. DOI: 10.1136/bmjopen-2021-053397.


MINDY1 promotes breast cancer cell proliferation by stabilizing estrogen receptor α.

Tang J, Luo Y, Long G, Zhou L Cell Death Dis. 2021; 12(10):937.

PMID: 34645792 PMC: 8514509. DOI: 10.1038/s41419-021-04244-z.


References
1.
Sparano J . TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006; 7(4):347-50. DOI: 10.3816/CBC.2006.n.051. View

2.
Banerjee S, Reis-Filho J, Ashley S, Steele D, Ashworth A, Lakhani S . Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006; 59(7):729-35. PMC: 1860434. DOI: 10.1136/jcp.2005.033043. View

3.
Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

4.
Goldhirsch A, Colleoni M, Domenighetti G, Gelber R . Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol. 2003; 14(8):1212-4. DOI: 10.1093/annonc/mdg327. View

5.
van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View